Should You Start Lithium with AST of 50 U/L?
Yes, you can safely start lithium therapy in a patient with a mildly elevated AST of 50 U/L, as lithium has no contraindications related to hepatic dysfunction and does not require baseline liver function monitoring.
Rationale Based on Evidence
Lithium and Liver Function: No Direct Relationship
The FDA label for lithium 1 lists contraindications as significant renal or cardiovascular disease, severe debilitation, dehydration, sodium depletion, and concurrent diuretic use—notably absent are any hepatic or liver enzyme-related contraindications. Lithium toxicity is related to serum lithium levels and renal clearance, not hepatic metabolism 1.
Understanding the AST Elevation Context
Your patient's AST of 50 U/L represents a mild elevation (<5 times the upper limit of normal), which falls into the mildest category of aminotransferase elevation 2. This level of elevation:
- Is extremely common, affecting approximately 10% of the U.S. population 3
- Most commonly reflects nonalcoholic fatty liver disease, alcoholic liver disease, or even non-hepatic causes 3
- Does not represent a contraindication to lithium therapy
Critical Distinction: AST vs. Hepatic Function
AST elevation does not equal hepatic dysfunction. The evidence clearly distinguishes between:
- Aminotransferases (AST/ALT): Markers of hepatocellular injury
- Actual hepatic synthetic function: Measured by albumin and prothrombin time 4
AST is particularly non-specific for liver disease, as it can be elevated from cardiac muscle, skeletal muscle, kidneys, brain, and red blood cells 2. In fact, some experts recommend limiting AST testing altogether due to its poor diagnostic specificity 5.
What You Should Actually Monitor
Before Starting Lithium:
- Renal function (creatinine, BUN, eGFR) - this is mandatory 1
- Thyroid function (TSH, free T4) 1
- Electrolytes (sodium, potassium)
- Cardiac assessment if indicated by history
- Pregnancy test in women of childbearing age
During Lithium Therapy:
- Serum lithium levels - critical for preventing toxicity 1
- Renal function - monitor regularly
- Thyroid function - lithium can cause hypothyroidism 1
- Clinical signs of toxicity - diarrhea, vomiting, drowsiness, weakness 1
Liver enzymes are NOT part of routine lithium monitoring protocols.
Common Pitfalls to Avoid
Don't confuse elevated AST with contraindication to lithium - there is no hepatic metabolism of lithium requiring dose adjustment for liver disease
Don't delay psychiatric treatment for a mild, isolated AST elevation that requires separate evaluation but doesn't impact lithium safety
Don't ignore the AST elevation entirely - while it doesn't affect lithium prescribing, you should still evaluate it according to standard algorithms for abnormal liver tests 4, 6:
- Review medications (including over-the-counter, herbs, supplements)
- Assess for metabolic syndrome risk factors
- Consider viral hepatitis screening if risk factors present
- Evaluate alcohol use
Focus monitoring on what matters for lithium - renal function and serum lithium levels are your safety priorities, not liver enzymes
The Bottom Line
The mildly elevated AST of 50 U/L should be evaluated on its own merits as a separate clinical issue, but it does not preclude starting lithium therapy. Lithium's therapeutic window and toxicity profile are entirely independent of hepatic function. Your monitoring should focus on maintaining therapeutic lithium levels (0.6-1.2 mEq/L for maintenance) and protecting renal function, not tracking liver enzymes.